Caption Management’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.55M Hold
63,500
0.01% 754
2025
Q4
$1.6M Sell
63,500
-4,300
-6% -$101K 0.01% 908
2025
Q3
$1.53M Buy
+67,800
New +$1.58M 0.01% 944
2025
Q2
Sell
-30,000
Closed -$656K 1421
2025
Q1
$656K Sell
30,000
-55,500
-65% -$1.53M 0.01% 1027
2024
Q4
$2.73M Buy
85,500
+25,500
+43% +$767K 0.03% 586
2024
Q3
$1.73M Sell
60,000
-103,900
-63% -$3.85M 0.03% 613
2024
Q2
$6.29M Buy
163,900
+103,900
+173% +$4.71M 0.1% 222
2024
Q1
$3.53M Sell
60,000
-179,300
-75% -$11.4M 0.05% 382
2023
Q4
$14.3M Sell
239,300
-15,700
-6% -$796K 0.19% 129
2023
Q3
$9.7M Buy
255,000
+125,000
+96% +$5.49M 0.15% 165
2023
Q2
$11.8M Sell
130,000
-140,500
-52% -$12.1M 0.21% 121
2023
Q1
$17.8M Buy
270,500
+200,500
+286% +$11.6M 0.34% 64
2022
Q4
$3.62M Buy
+70,000
New +$3.71M 0.06% 398
2022
Q2
Sell
-648,700
Closed -$33M 1420
2022
Q1
$33M Buy
648,700
+428,700
+195% +$18.9M 0.4% 40
2021
Q4
$10.4M Sell
220,000
-365,300
-62% -$14.4M 0.12% 222
2021
Q3
$19.3M Buy
585,300
+400,300
+216% +$22.5M 0.22% 100
2021
Q2
$11.7M Buy
+185,000
New +$9.55M 0.15% 165
2020
Q4
Sell
-30,000
Closed -$904K 955
2020
Q3
$904K Buy
+30,000
New +$896K 0.02% 641

Other funds holding APLS

Caption Management's APLS Position: Q1 2026 in Review

Caption Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 254,563 shares — an estimated $5.49M sold.

Caption Management first reported a position in APLS in Q1 2021 and held it in 15 quarters. The position peaked at $23.5M in Q4 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Caption Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 254,563 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.49M.
  • Caption Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 15 quarters.
  • Caption Management's Apellis Pharmaceuticals position peaked at $23.5M in Q4 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.